Adaptive Phage Therapeutics logo

Adaptive Phage Therapeutics Funding & Investors

Gaithersburg, MD

Adaptive Phage Therapeutics (APT) is a clinical-stage company advancing therapies addressing multi-drug resistant infections. Prior antimicrobial therapeutic approaches have been “fixed,” while pathogens continue to evolve resistance to each of those therapeutics, causing those drug products to beco... Read more

aphage.com

Total Amount Raised: $131,684,384

Adaptive Phage Therapeutics Funding Rounds

  • Series B

    $12,000,000

    Series B Investors

    AMR Action Fund
    Deerfield Capital Management
  • Grant

    $5,000,000

    Grant Investors

    Defense Health Agency
  • Series B

    $20,000,000

    Series B Investors

    AMR Action Fund
  • Series B

    $40,750,000

    Series B Investors

    Deerfield Management
    Mayo Clinic
  • Convertible Note

    $6,175,000

    Convertible Note Investors

    Mayo Clinic
  • Grant

    $33,000,000

    Grant Investors

    US Department Of Defense
  • Series Unknown

    $7,000,000

    Series Unknown Investors

    Alexandria Venture Investments
  • Debt Financing

    $6,994,388

  • Seed

    $765,000

Funding info provided by Diffbot.